MoonLake Immunotherapeutics reports results for the quarter ended December 31 - Earnings Summary

MoonLake Immunotherapeutics

26/02/2025 14:32

MoonLake Immunotherapeutics MLTX.OQ reported a quarterly adjusted loss of 72 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of fourteen analysts for the quarter was for a loss of 60 cents per share. Wall Street expected results to range from -76 cents to -39 cents per share.

Reported revenue was zero​; analysts expected zero.

MoonLake Immunotherapeutics's reported EPS for the quarter was a loss of 72 cents​.

The company reported a quarterly loss of $45.6 million.

MoonLake Immunotherapeutics shares had fallen by 24.8% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $76.00

This summary was machine generated from LSEG data February 26 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.60
-0.72
Missed
Sep. 30 2024
-0.44
-0.56
Missed
Jun. 30 2024
-0.28
-0.39
Missed
Mar. 31 2024
-0.19
-0.22
Missed